Aurelie Ruet

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.

Journal: Annals of clinical and translational neurology
Published: June 12, 2026

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 02, 2026

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

Journal: Neurology
Published: May 22, 2026

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology
Published: May 05, 2026

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: April 28, 2026

Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.

Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.

Journal: Journal of neurology
Published: April 17, 2026

Interthalamic adhesion alterations in multiple sclerosis: associations with thalamic damage and cognition.

Interthalamic adhesion alterations in multiple sclerosis: associations with thalamic damage and cognition.

Journal: Journal of neurology
Published: April 11, 2026

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA neurology
Published: March 23, 2026

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Journal: Multiple sclerosis and related disorders
Published: March 05, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 13, 2026

The constrained brain in multiple sclerosis: Cognitive impairment is related to network-specific coupling of structural and functional connectivity.

The constrained brain in multiple sclerosis: Cognitive impairment is related to network-specific coupling of structural and functional connectivity.

Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: December 23, 2025

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.

Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 17, 2025
Showing 1-12 of 131

Last Updated: 09/26/2026